Close MenuClose
Close Menu
George P Hemstreet, MD, PhD

Professor

George Hemstreet

Contact

School of Medicine
Department of Urology Fellowships

George P Hemstreet, MD, PhD

Professor

Dr. Hemstreet as a clinician scientist obtained his Ph.D. following his medical training in Microbiology and Immunology. After completing his surgical residency his career developed as a clinical urologist and basic science researcher by utilizing his immunological background as it applied to tumor immunology and infectious disease and later to biophysical cytochemistry. Subsequently his career interests focused on the development of and validation of quantitative fluorescence image analysis for assaying proteins in single cells and more recently to the area of tissues proteomics (zeptomole level with a 15% variance). Early in his career he pioneered the field of molecular epidemiology and biomarkers when he scientific and medical director of Notification and Screening Program for workers exposed to aniline dyes sponsored by Workers Institute and NIOSH. This study contributed to defining the then new discipline of molecular epidemiology. The microscope based fluorescence technique used in this study was automated incorporating fluorescence imaging. This technology was later recognized by the National Research Council where Dr. Hemstreet served as Vice Committee for the committee on Biomarkers in Urinary Toxicology. The two year sojourn spawned the EDRN and served as a basis for increasing the funding for cancer prevention at the NCI. This leadership imitative was preceded by the programming of a fluorescence microscope for single cell proteomics. The sensitivity of this methodology defined alterations in nuclear and cytoplasmic actin depolymerization (G-actin/F-actin ratio) explaining the cardinal single cell signature of malignancy (nuclear cytoplasmic ratio). The instrumentation and the analysis of over 15,000 samples scientifically validated Slaughter”s hypothesis of molecular field disease in bladder cancer biopsy specimens which subsequently was further verified by a large bladder cancer six year longitudinal cohort study in five Chinese provinces. These concepts were vitally important for the integrated conceptual appreciation of biomarkers as it related to defining malignant associated dysplasia’s (Linxien Study) that heralded the malignant cancer phenotype. During these studies Dr. Hemstreet was the founder of a biomedical research company CytoDiagnostics which became the centerpiece and financial backbone for the establishment the Biomedical Research Park Associated with the University of Oklahoma Medical Center. The role of biomarkers for pharmacological monitoring of drug effects on cellular differentiation so key to chemoprevention was introduced. More recently, a method was developed for studying the proteomic changes in the human tissues microenvironment, a concept initially hypothesized in the National Research Council Report.

Teaching Interests

  • Urologic Oncology, Immunology, Biomarkers in Molecular Biology

Department

Urology

Position

Professor

Articles

  • Prostate
    Zhou CK, Stanczyk FZ, Hafi M, Veneroso CC, Lynch B, Falk RT, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll PR, Manyak MJ, Sesterhenn IA, Levine PH, Hsing AW, Cook MB. Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers. Prostate. 2017 Dec;77(16):1573-1582. doi: 10.1002/pros.23433. Epub 2017 Oct 2. PubMed PMID: 28971497; PubMed Central PMCID: PMC5683095. 
    77(16), p. 1573-1582 2017
  • Rare Tumors
    Wang J, Wang FW, LaGrange CA, Hemstreet GP. Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. PMID: 20141680
    2(3), p. e47 130-34 2010
  • Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Struop AM, Wake R, Wei JT. “NCCN Clinical Practice Guidelines in Oncology: Prostate cancer early detection.” J Natl Compr Caner Network, PMID: 20141680
    8(2), p. 240-62 2010

Publications

  • J Natl Compr Canc Netw
    Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. PubMed PMID: 27160230. 
    14(5), p. 509-19 2016
  • Hemstreet GP 3rd, Rossi GR, Pisarev VM, Enke CA, Helfner L, Hauke RJ, Tennant L, Ramsey WJ, Vahanian NN, Link CJ, . Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. J Immunother
    36(1), p. 57-65 2013
  • Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP 3rd, Crawford ED, Thompson IM Jr, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology
    79(3), p. 633-637 2012
  • Kaushik D, Teply BA, Hemstreet GP 3rd. Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer : Use of 980-nm diode laser. Lasers Med Sci. PMID: 22370618, DOI: 10.1007/s10103-012-1070-y
    27(5), p. 1099-1102 2012
  • Wang J, Wang FW, LaGrange CA, Hemstreet GP. Younger Age is an Independent Predictor for Poor Survival in Patients with Signet Ring Prostate Carcinoma. Prostate Cancer. doi:10.1155/2011/216169
    vol. 2011, Article ID 216169, p. 8 pages 2011
  • Park ES, Boedeker BH, Hemstreet GP. The Initiation of a Preoperative and Postoperative Telemedicine Urology Clinic. Stud Health Technol Inform
    163, p. 425-7 2011
  • Villanueva, C. Hemstreet GP. The approach to the Difficult Urethral Catheterization Among Urology Residents in the United States. Int Braz J Urol
    Nov-Dec;36(6), p. 710-5; discussion 715-7. 2010
  • Wang J, Wang FW, Hemstreet GP 3rd. Younger age is an independent predictor for poor survival in patients with signet ring prostate carcinoma. Prostate Cancer. PMCID: PMC3216005, DOI: 10.1155/2011/216169
    2011, p. PMID: 22110982 2010
  • Current Urology Reports
    Villanueva C, Hemstreet GP 3rd. Experience with a Difficult Urethral Catheterization Algorithm at a University Hospital 2010
  • Huang D, Casale G, Tian J, Lele S, Pisarev V, Simpson M, Hemstreet GP. “UDP-glucose deydrogenase as a novel field-specific candidate biomarker of prostate cancer. Int J Cancer
    126(2), p. 315-27 2010
  • Urology
    Richardson T, McCanse W, Casale G, Huang D, Tian J, Elkahwaji J, Subodh L, Hemstreet GP. “Tissue based quantification of 8-hydroxy-2’deoxyguanosine (8-OhdG) in human prostate biopsies using quantitative fluorescence imaging analysis”
    74(5), p. 1174-9 2009
  • Villanueva C, Hemstreet GP 3rd. Difficult male urethral catheterization: a review of different approaches. Int Braz J Urol
    Jul-Aug;34(4), p. 401-11; discussion 412 2008
  • Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res
    14(1), p. 224-9 2008
  • Carreón T, Kadlubar FF, Ruder AM, Schulte PA, Hayes RB, Waters M, Grant DJ, Boissy R, Bell DA, Hemstreet GP 3rd, Yin S, Lemasters GK, Rothman N. Reply to the letter to the Editor: “N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis”. Int J Cancer
    121(7), p. 1637-9; author reply 1640-1 2007
  • Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet, GP 3rd,Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Pattersonn S, Pollack S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT: National comprehensive network. “Prostate cancer early detection. Clinical practice guidelines in oncology”
    5(7), p. 714-36 2007
  • Huang D, Casale GP, Tian J, Wehbi N, Abrahams NA, Kaleem Z, Smith LM, Johansson SL, Elkahwaji JE, Hemstreet GP 3rd. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to β-Catenin in archived prostate specimens. 2007Jul; . Cancer Epidemiol, Biomarkers Prev
    (16)7:, p. 1371-1381 2007
  • Lewis TE, Milam TD, Klingler DK, Rao PS, Jaggi M, Smith DJ, Hemstreet GP and K.C. Balaji; Tissue Transglutaminase Interacts with protein kinase A anchor protein 13 in prosate cancer. Urol Oncol. 2005, Nov-Dec;
    23(6), p. 407-12 2006
  • Carreon T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, Hemstreet GP, Yin S, LeMasters GK. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer
    18(1), p. 161-8 2006
  • Urology
    Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers; Urology
    66(6 Suppl 1), p. 64-74 2005
  • Urology
    Lokeshwar VB, Habuchi T, Grossman, HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
    66 (6 suppl 1), p. 35-63 2005
  • Lewis TE, Milam TD, Klingler DK, Rao PS, Jaggi M, Smith DJ, Hemstreet GP and K.C. Balaji; Tissue Transglutaminase Interacts with protein kinase A anchor protein 13 in prosate cancer. Urol Oncol
    23(6), p. 407-12 2005
  • Urology
    Klinger DW, Hemstreet GP, Balaji KC, Feasibility of robotic radical nephrectomy – Initial results of a single institution pilot study
    65(6), p. 1086-9 2005
  • Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP, Balaji KC. E-cadherin Phosphorylation by protein kinase D1/protein kinase C (mu) is associated with altered cellular aggregation and motility in prostate cancer; Cancer Res
    65:(2), p. 483-492 2005
  • Hemstreet GP, Wang W. Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine). Front Biosci
    9, p. 2671-9 2004
  • Urology
    Balaji KC, Yohannes P, McBride CL,Oleynikov D. Hemstreet GP. Feasibility of robot-assisted totally intracorporeal laparoscopic ileal conduit urinary diversion: initial results of a single institutional pilot study
    63(1), p. 51-5 2004
  • Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji KC. Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun
    310(3):, p. 1032-8 2003
  • Jaggi M, Rao PS, Smith DJ, Hemstreet GP, Balaji KC. Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochem Biophys Res Commun
    307(2), p. 254-60 2003
  • Anticancer Res.
    Hurst RE, Kyker KD, Bonner RB, Bowditch RD, Hemstreet, GP. Matrix-dependent plasticity of the malignant phenotype of bladder cancer cells
    23(4), p. 3119-28 2003
  • Hemstreet GP, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, Zang M, Zheng Q, Bane B, Asal N, Li G, Feng P, Hurst RE, Wang W. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine: J Natl Cancer Inst
    93(6), p. 427-36 2003
  • Oncology
    Hemstreet GP III. Erectile dysfunction is associated with brachytherapy, conformal radiation, or radical surgery
    17(1), p. 68-70 2003
  • Journal of Urology
    Wehbi,NK, Dugger AL, Bonner RB, Pitha JV, Hurst RE, Hemstreet GP. Pan-cadherin as a high level phenotypic biomarker for prostate cancer
    167(5), p. 2215-21 2002
  • Biotechniques
    Rao J, Seligson D, Hemstreet GP: Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides
    32(4), p. 924-6, 928-30, 932 2002
  • Cancer
    Birckbichler, PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, and Hemstreet GP. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma
    89(2), p. 412-13 2000
  • Cancer Detection and Prevention.
    Hemstreet, GP, Bonner RB, Hurst RE, Bell D, Bane BL. Abnormal G-Actin content in single prostate cells as a biomarker for prostate cancer. PMID 11129989
    24(5), p. 464-72 2000

Editing and Reviews

  • Journal of Urology
    Hemstreet GP. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. (Editorial comment)
    166(5), p. 1665 2001

Awards

  • Unemed New Invention Contributor 2009
    UNMC
  • Citation for Meritorious Services to the Oklahoma City Bombing Victims
    American Medical Association
  • Biological Markers in Urinary Toxicology
    National Research Council, ed. Washington, DC
  • Honorable Visiting Professor
    Department of Urological Oncology, Cancer Institute (Hospital)
    Chinese Academy of Medical Sciences, Beijing, China
  • George Lynn Cross Research Professorship
    The University of Oklahoma
  • Visiting Professor
    Department of Urology, Chongging Cancer Institute, Beijing, China
    Chinese Academy of Preventive Medicine
  • Young Investigators Award
    NIH